The de-linkage of R - Combination drug - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2012-05-15 11:38:15 Gilead Sciences Fixed dose combination Bristol-Myers Squibb Carbamates Medicine AIDS Emtricitabine/tenofovir/efavirenz HIV Antiretroviral drug HIV/AIDS Chemistry Organic chemistry		The de-linkage of R&D costs and drug prices through the Prize Fund for HIV/AIDS will cost less, expand access, accelerate and improve innovation, and replace an incentive system that is expensive, inefficient and unsusta Add to Reading List Source URL: www.help.senate.gov Download Document from Source Website File Size: 214,83 KB Share Document on Facebook

	BMS_Gilead_Logo_FINAL.eps DocID: 1m38a - View Document
	Patient Information ATRIPLA® (uh TRIP luh) Tablets ALERT: Find out about medicines that should NOT be taken with ATRIPLA. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA." Generic name: efaviren DocID: 1lg5I - View Document
	This is an electronically controlled document. User is responsible to verify and use the current revision. GENERAL CONFORMITY CERTIFICATE Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a DocID: 1azYS - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION  New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess estimated creatinine DocID: 1ah6Z - View Document
	Microsoft Word - FPC QHP Policy Guide Febdoc DocID: 19ARO - View Document